Isothermal Nucleic Acid Amplification Technology (INAAT) Market worth $1,651 Million by 2018

 Isothermal Nucleic Acid Amplification Technology (INAAT) Market worth $1,651
                               Million by 2018

  PR Newswire

  DALLAS, May 16, 2014

DALLAS, May 16, 2014 /PRNewswire/ --

According to the new market research report " Isothermal Nucleic Acid
Amplification Technology (INAAT) Market  by Application (Infectious Diseases,
Blood Screening, Research), Products (Instruments, Reagents), End-User
(Hospital, Reference Laboratories, Other) - Global Forecast to 2018 ",
published by MarketsandMarkets, the global Isothermal Nucleic Acid
Amplification Technology (INAAT) Market is poised to reach $1,651 Million by
2018 at a CAGR of 13.5%.

Browse 31 market data  Tables and 53 Figures spread through 215 P ages and
in-depth TOC on "Isothermal Nucleic Acid Amplification Technology (INAAT) "

http://www.marketsandmarkets.com/Market-Reports/isothermal-nucleic-acid-amplification-technologies-inaat-market-839.html

Early buyers will receive 10% customization on this report. 

The increasing demand for enhanced molecular testing using INAAT as well as
rising incidence of infectious diseases is driving market growth over the
conventional thermal polymerase chain reaction (PCR) technology.

In addition to increasing population suffering from infectious disease and
cancer, promise for less expensive molecular testing using INAAT, better
throughput in gene amplification, and advent of novel technologies such as
Loop-Mediated Isothermal Amplification (LAMP), Nucleic Acid Sequence Based
Amplification (NASBA) and Helicase Dependent Amplification (HDA) play pivotal
role in propelling market momentum. On the other hand, inadequate advanced
infrastructure and higher dependency on convention method (PCR technology)
restrict market growth globally.

Amongst various applications of INAAT, prognosis and diagnosis of infectious
disease allows a huge scope for market penetration of novel isothermal
technologies such as Loop-Mediated Isothermal Amplification (LAMP), Nucleic
Acid Sequence Based Amplification (NASBA) and Helicase Dependent Amplification
(HDA) among others. Infectious disease application market, especially sexually
transmitted disease (STD) and hepatitis A & B, is expected to witness a double
digit growth rate during the forecast period. Moreover, blood screening
application is also expected to be a significant revenue pocket of INAAT due
to increasing practice of mandatory testing of donated blood at blood donation
unit to ensure the quality of blood sample.

End-users analysis identified reference laboratory as a potential segment
ensuring a rapid growth of various isothermal amplification technologies in
different complex molecular testing; whereas, technology roadmap analysis
expected a rapid adoption of single miniaturized devices in the global
molecular diagnostics industry.

Various private investors, venture capital firms (Bill & Melinda Gates
Foundation, Wellcome Trust), and public funding bodies (the National
Institutes of Health and the Centers for Disease Control and Prevention) were
found to be significant investors encouraging speedy penetration of advanced
isothermal technologies. On the other hand, demand side analysis considered
portability and affordability the major factors contributing the competitive
edge to isothermal technologies as compared to convention PCR technology.

Increasing prevalence rate of infectious diseases and significant adoption of
novel technologies are expected to ensure a double digit growth in emerging
nations, especially in India, China, South Africa, Singapore, and Middle East.
However, INAAT in developed countries is also expected to witness a steady
grow in the diagnosis of various infectious diseases such as
healthcare-associated infections and sexually transmitted diseases.

The key players in the Isothermal Nucleic Acid Amplification Technology
(INAAT) M arket include Alere, Inc. (U.S.), Becton, Dickinson & Company
(U.S.), BioHelix (U.S.), bioMerieux (France), Hologic Gene-Probe (U.S.), and
QIAGEN (The Netherlands).

 Browse related reports 

Genomics Market by Products - [Instruments (NGS platform, Microarray, RT-PCR),
Consumables (Genechips, Reagents for DNA Extraction & Purification,
Sequencing)], Services (Sequencing & Microarray Services, and Software) -
Global Forecast to 2018.
http://www.marketsandmarkets.com/Market-Reports/genomics-market-613.html

 Molecular Diagnostics Market - Technologies [PCR, DNA Sequencing,
Microarray, Transcription Mediated Amplification, Hybridization], Applications
Virology/Infectious Diseases, Cancer/ Oncology, Genetic Testing, Blood
Screening, Microbiology] Global Opportunities, Competitor Analysis & Forecasts
to 2017

http://www.marketsandmarkets.com/Market-Reports/molecular-diagnostic-market-833.html

About MarketsandMarkets 

MarketsandMarkets is a global market research and consulting company based in
the U.S. We publish strategically analyzed market research reports and serve
as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles,
databases, and custom research services. MarketsandMarkets covers thirteen
industry verticals, including advanced materials, automotive and
transportation, banking and financial services, biotechnology , chemicals,
consumer goods, energy and power, food and beverages, industrial automation,
medical devices, pharmaceuticals, healthcare IT semiconductor and electronics,
and telecommunications and IT.

We at MarketsandMarkets are inspired to help our clients grow by providing apt
business insight with our huge market intelligence repository.

Contact: Mr. Rohan North - Dominion Plaza, 17304, Preston Road, Suite 800,
Dallas, TX 75252 Tel: +1-888-600-6441 Email: sales@marketsandmarkets.com

Visit MarketsandMarkets Blog
http://www.marketsandmarketsblog.com/market-reports/healthcare/biotechnology
Connect with us on LinkedIn @
http://www.linkedin.com/company/marketsandmarkets
 
Press spacebar to pause and continue. Press esc to stop.